Qudexy XR (Oral)

Generic name:topiramate (oral route) [ toe-PIR-a-mate ]
Drug class:Carbonic anhydrase inhibitor anticonvulsants

Medically reviewed by Drugs.com. Last updated on Apr 25, 2022.

Commonly used brand name(s)

In the U.S.

• Eprontia
• Qudexy XR
• Topamax
• Topiragen
• Trokendi XR

Available Dosage Forms:

• Tablet
• Capsule, Extended Release
• Solution
• Capsule

Therapeutic Class: Anticonvulsant

Chemical Class: Fructopyranose Sulfamate

Uses for Qudexy XR

Topiramate is used alone or together with other medicines to help treat certain types of seizures (eg, partial seizures, tonic-clonic seizures, or Lennox-Gastaut syndrome). This medicine will not cure epilepsy and will only work to control seizures for as long as you continue to take it. It is also used to help prevent migraine headaches.

This medicine is available only with your doctor's prescription.

Before using Qudexy XR

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of topiramate capsules, oral solution, or tablets, or Qudexy® extended-release capsules to treat seizures in children younger than 2 years of age (when used alone or together with other medicines). However, children are more likely to have unwanted effects (eg, rickets, slow growth, and increased risk of kidney stones) to this medicine. Safety and efficacy have not been established.

Appropriate studies have not been performed on the relationship of age to the effects of Trokendi™ extended-release capsules for the treatment of seizures in children younger than 6 years of age.

Appropriate studies have not been performed on the relationship of age to the effects of topiramate capsules, extended-release capsules, tablets, or oral solution for the prevention of migraine headaches in children younger than 12 years of age. Safety and efficacy have not been established.

Geriatric

Although appropriate studies on the relationship of age to the effects of topiramate have not been performed in the geriatric population, geriatric-specific problems are not expected to limit the usefulness of topiramate in the elderly. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving topiramate.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this m...